Binex Signs Record-Breaking 20.8 Billion KRW CMO Production Contract

On September 8, Binex announced that it had signed a biosimilar production contract worth 20.8 billion KRW with a global bio company. This contract is the largest ever for a single product, accounting for 16.01% of the company's most recent annual sales and 45.61% of its CDMO (Contract Development and Manufacturing Organization) biopharmaceutical sales.

Through this contract, the company plans to begin full-scale production of the product in December this year and supply the entire order by next year.

Binex has successfully passed inspections by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), proving its world-class production and quality management systems. The company has recently secured a series of large-scale production contracts with global pharmaceutical and bio companies, rapidly strengthening its position as a global CDMO partner.

Additionally, Binex is actively participating in major global exhibitions such as BIO USA 2025 and Interphex Week Tokyo 2025, focusing on expanding overseas partnerships, networking, and accelerating its efforts to pioneer new markets.

A Binex representative stated, "This large-scale contract not only signals the full-fledged entry into the U.S. and European markets, but also demonstrates the growth momentum as global orders continue to increase," adding, "We will continue to pursue sustained growth in the future."

This content was produced with the assistance of AI translation services.